Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

SciClone Pharmaceuticals Inc.

(SCLN)

Franklin Berger of Josephthal Lyon & Ross reiterated a "buy,"

Read the full 148 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE